Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 5/20 | 0.31 |
| ▸ | SOAT1 | P35610 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8771324 | 1.00 | CYP2C9 (0.43) | CYP2C9ALDH1A1LMNAMAPTMEN1 | |
| SCHEMBL8771419 | 0.92 | CYP2C9 (0.36) | CYP2C9ALDH1A1LMNAMAPTMEN1 | |
| SCHEMBL8771423 | 0.92 | CYP2C9 (0.36) | CYP2C9ALDH1A1LMNAMAPTMEN1 | |
| SCHEMBL15460640 | 0.89 | CYP2C9 (0.36) | CYP2C9ALDH1A1LMNAMAPTMEN1 | |
| SCHEMBL13198626 | 0.87 | CYP2C9 (0.38) | CYP2C9ALDH1A1LMNAMAPTMEN1 | |
| SCHEMBL15460628 | 0.87 | ALDH1A1 (0.38) | CYP2C9ALDH1A1LMNAMAPTMEN1 | |
| SCHEMBL8728168 | 0.86 | CYP2C9 (0.36) | CYP2C9ALDH1A1LMNAMAPTMEN1 | |
| SCHEMBL15461036 | 0.85 | CYP2C9 (0.34) | CYP2C9ALDH1A1LMNAMAPTMEN1 | |
| SCHEMBL13198623 | 0.85 | CYP2C9 (0.38) | CYP2C9ALDH1A1LMNAMAPTMEN1 | |
| SCHEMBL2741557 | 0.84 | ESR2 (0.42) | CYP2C9ESR2FFAR4CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9683172-B2 | Liquid crystal composition and liquid crystal display including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-06-20 | — | — | US | disclosed |
| US-9683172-B2 | Liquid crystal composition and liquid crystal display including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-06-20 | — | — | US | disclosed |
| US-20160257881-A1 | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2016-09-08 | — | — | US | disclosed |
| US-20160257881-A1 | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2016-09-08 | — | — | US | disclosed |
| US-9422477-B2 | Liquid crystal compositon and liquid crystal display including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2016-08-23 | — | — | US | disclosed |
| US-9422477-B2 | Liquid crystal compositon and liquid crystal display including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2016-08-23 | — | — | US | disclosed |
| US-20160122645-A1 | LIQUID CRYSTAL COMPOSITON AND LIQUID CRYSTAL DISPLAY INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2016-05-05 | — | — | US | disclosed |
| US-20160122645-A1 | LIQUID CRYSTAL COMPOSITON AND LIQUID CRYSTAL DISPLAY INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2016-05-05 | — | — | US | disclosed |
| US-7785675-B2 | Compound and liquid crystal composition | ADEKA CORPORATION (JP) | 2010-08-31 | — | — | US | disclosed |
| US-20090103041-A1 | Novel compound and liquid crystal composition | ADEKA CORPORATION (JP) | 2009-04-23 | — | — | US | disclosed |
| EP-0799878-A1 | Liquid crystal compositions and liquid crystal display elements containing same | Shin-Etsu Chemical Co., Ltd. (JP) | 1997-10-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160257881-A1 | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY INCLUDING THE SAME | CLIC4, HCFC1, CALCOCO2 | CYP2C9 2971/4885ALDH1A1 2455/4885LMNA 1332/4885 |
| US-20090103041-A1 | Novel compound and liquid crystal composition | PYM1, H1-0, H1-2 | CYP2C9 800/4885ALDH1A1 2016/4885LMNA 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.